Acute Coronary Syndromes. Characteristics, management and prognosis in relation to gender and type of syndrome by Perers, Elisabeth
 
 
 
 
Elisabeth Perers                       Acute Coronary Syndromes 
 
 
 
 
 
 
 
 
 
Acute Coronary Syndromes 
 
Characteristics, management and prognosis in  
relation to gender and type of syndrome 
 
 
 
 
 
Acute Coronary Syndromes 
 
Characteristics, management and prognosis in relation to gender and 
type of syndrome 
 
 
Elisabeth Perers 
 
 
 
 
 
 
 
 
 
 
Göteborg 2006  
 
 
 
 
 
 
 
From the Cardiovascular Institute 
Department of Cardiology 
The Sahlgrenska Academy at 
Göteborg University, Göteborg, Sweden 
 
 
 
 
 
Elisabeth Perers                       Acute Coronary Syndromes 
 
 
 
 
Elisabeth Perers                       Acute Coronary Syndromes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute Coronary Syndromes 
Characteristics, management and prognosis in relation to gender and type of syndrome 
 
By: Elisabeth Perers 
Printed at: Vasatryckeriet i Göteborg AB 
 
ISBN 91-628-6964-7 
 
 
 
 
Elisabeth Perers                       Acute Coronary Syndromes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
 
 
CONTENTS 
 
 
ABSTRACT               …………………..……….   7 
LIST OF ORIGINAL PAPERS          ……………………………   8 
ABBREVIATIONS             …………………..………..    9 
INTRODUCTION             ……………………………     10 
Pathophysiology             ……………………………     10 
Definitions and clinical manifestations       ……………………………     10  
Quality of life in coronary artery disease      ……………………………     11 
Gender perspectives in coronary artery disease    ……………………………     11 
Age perspectives in coronary artery disease     …..…………………………     12 
Management and treatment          …..…………………………     13 
Prognosis               …..…………………………     13 
AIMS                 …..…………………………     15 
METHODS AND MATERIAL          …..…………………………     16 
 Study population             …..…………………………     16 
Data collection             …..…………………………     17 
Quality of Life Instrument (paper 3 )       …..…………………………     17 
General comments            …..…………………………     17 
STATISTICS               …..…………………………           19 
RESULTS               …..…………………………     20 
 Observations in Relation to Gender       …..…………………………     20 
Observations in Relation to Type of ACS       …..…………………………     21 
Observations in Relation to Age        …………….………………     23 
Quality of Life             …..…………………………     24 
Characteristics in UAP versus MI        …..…………………………     25 
CHP in UAP vs MI            …..…………………………       25 
QoL in Relation to Characteristics of ACS Patients   …..…………………………       25 
Multivariable Analysis of CHP in UAP vs. MI    …..…………………………       26 
DISCUSSION              …..…………………………       27 
 Findings in Relation to Gender         …..…………………………       27 
 Findings in Relation to Type of Syndrome      …..…………………………       29 
 Findings in Relation to Quality of Life       …..…………………………       31 
 Findings in Relations to Age         …..…………………………       32 
SUMMARY               ..……………………………       34 
ACKNOWLEDGEMENTS           …..…………………………       35 
APPENDIX               …..…………………………       36 
REFERENCES              …..…………………………       37 
 
 
  
 
Elisabeth Perers          7       The Spectrum of  Acute Coronary Syndromes 
ABSTRACT 
____________________________________________________________________________________ 
 
Background: Acute coronary syndromes (ACS) represent a wide spectrum of conditions from 
ST-elevation myocardial infarction (STEMI) to unstable angina pectoris (UAP). Randomized 
trials tend to focus on ST-elevation myocardial infarction (STEMI) or non-ST-elevation ACS, 
and consequently studies providing data on the entire condition are relatively scarce, especially 
with information including long-term follow-up.      
 
Methods: We studied 1744 consecutive patients under 80 years of age admitted to the coronary 
care unit (CCU) at Sahlgrenska University Hospital with ACS between Sept 1995 and Sept 1999. 
The patients were divided into four groups with assumed decreasing order of severity on the 
basis of ECG and biochemical markers; STEMI, non STEMI and UAP of high-and low-risk 
types. Three different age groups were also created (<65, 65-74 and 75-79 years). All patients 
were followed for 5 years with regard to total mortality and for 45 months with respect to 
cardiovascular morbidity and mortality. The main objectives were to study differences in 
baseline characteristics, clinical presentation, treatment, early as well as long-term morbidity and 
mortality in relation to gender, type of syndrome and age.     
 
Results: Women were older than men, less likely to seek early medical care, and in the younger 
age group more likely to present with hypotension. No significant differences in treatment were 
observed. Reperfusion was used to a similar extent in women and men, but there was a non 
significant tendency to use percutaneous coronary intervention (PCI) more often in men. Women 
did not suffer from more severe complications or early deaths. Among women and men 
surviving the acute phase there was no difference in long-term mortality (21.0% and 18.2%, 
respectively). After adjustment for age differences the hazard ratio (HR) and corresponding 
confidence interval (CI) for a higher late 5 year mortality in women in relation to men was 0.89 
(0.70-1.13), p=0.34. The crude rate of rehospitalization for congestive heart failure was 
significantly higher in women, a significance that disappeared after adjustment for age. While 
short-term mortality was highest in STEMI, the non STEMI patients did worse in the long run. 
Non STEMI was associated with a significantly higher long-term mortality than STEMI, before 
but not after adjustment for co-variates (HR and 95% CI 1.02 [0.75-1.37], p=0.92). Of these, age, 
ST-depression on admission and early revascularization with PCI seemed to be of particular 
importance. 
    Elderly patients had a more complicated course of the disease, were less frequently subjected 
to coronary angiographies and PCI, and had a poorer outcome. Patients with UAP, especially of 
the low-risk type, experienced poorer quality of life following ACS than patients with other 
types of ACS. 
 
Conclusion: Among patients <80 years with ACS admitted to a CCU, the suspicion that women 
are treated less aggressively and suffer from more complications including mortality than men 
could not be verified. Only small gender differences were observed. With respect to type of 
syndrome we could demonstrate a higher long-term mortality in non STEMI, which disappeared 
after adjustment for variables with a significant impact on prognosis.  
 
Key words: Acute coronary syndromes, gender, age, treatment, quality of life, outcome 
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ABBREVIATIONS 
____________________________________________________________________________________________ 
 
 
ACE   Angiotensin Converting Enzyme 
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AF    Atrial Fibrillation  
BPM   Beats Per Minute  
BMI   Body Mass Index 
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CAD   Coronary Artery Disease 
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ED    Emergency Department  
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INTRODUCTION 
___________________________________________________________________________ 
 
    Acute coronary syndrome (ACS) is a 
major cause of morbidity and mortality in 
Sweden and worldwide. ACS comprises a 
broad spectrum of clinical conditions from 
unstable angina pectoris (UAP) with no 
ischemic ECG changes or biochemical 
evidence of myocardial necrosis to ST- 
segment elevation myocardial infarction 
(STEMI) and sudden coronary death. 
Manifestations of coronary artery disease 
(CAD) in populations undergo rapid 
changes over time. In many countries the 
incidence of myocardial infarction (MI) 
and the mortality from CAD is decreasing 
1,2 Furthermore, the severity of ACS has 
changed due to effective preventive 
measures together with improvements in 
management and treatment3. In spite of 
these positive trends ACS continues to be 
associated with considerable morbidity and 
mortality.  
 
Pathophysiology 
    Coronary atherosclerosis starts early in 
life. Coronary lesions are present in the 
majority of young adults, particularly in 
western countries. Proliferation of smooth 
muscle cells, matrix synthesis, and lipid 
accumulation may narrow the arterial 
lumen gradually and lead to myocardial 
ischemia and anginal pain, but survival is 
good if thrombotic complications can be 
prevented4,5. Atherosclerosis is primary 
located in the intimae of the vessel wall. A 
healthy endothelium functions as a 
selective lipoprotein–permeable barrier.  
    Dysfunction of the endothelium can be 
caused by stress, turbulent blood flow and 
factors such as diabetes, smoking, 
hyperlipidemia, hypertension and /or 
genetic mechanisms6. During the last 
decades inflammatory reactions are 
recognized to be involved in the process of 
atherosclerosis. In the presence of endo-
thelium dysfunction, inflammatory cells 
and lipid laden foam cells will migrate into 
the arterial vessel wall7. Atherosclerotic 
plaque formation is a slow and insidious 
process, which can continue for many 
years before overt symptoms. The 
mechanism responsible for the sudden 
conversion from a stable disease into a 
life–threatening condition is either 
endothelial erosion or plaque disruption, 
the former more common in women and 
the latter in men, both triggering 
thrombosis formation8,9. The risk of plaque 
disruption depends more on plaque 
vulnerability and thrombogenecity than on 
plaque size or severity of stenosis10,11. 
    Coronary plaques are constantly stressed 
by a variety of biochemical, mechanical 
and hemodynamic forces that may 
precipitate or “trigger” disruption.  
    Following disruption, haemorrhage into 
the plaque, luminal thrombosis, embo-
lization of thrombotic material and/or 
vasospasm may cause sudden flow 
obstruction, giving rise to new or changing 
symptoms. The culprit lesion is frequently 
“dynamic”, causing intermittent flow 
obstruction, and clinical presentation and 
outcome depend on the severity and 
duration of myocardial ischemia5,12 The 
challenge is to identify and treat the 
dangerous vulnerable plaques responsible 
for the life-threatening ACS. To remove 
the angina–producing stenotic lesions is 
not enough. Culprit lesion-based inter-
ventions usually eliminate anginal pain, 
but do not substantially improve the long–
term outcome. MI and death depend more 
on co-existing non-symptomatic vulnerable 
plaque than on stenotic angina-producing 
lesions13  
 
Definitions and clinical manifestations 
  Acute MI is defined as myocardial 
necrosis secondary to interruption of 
coronary blood supply. However, as these 
findings can only be confirmed histo-
logically, the clinical diagnosis is based on 
the history, ECG findings and elevated 
biochemical markers indicating myocardial 
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damage. Modern classification of MI 
differentiates between ST elevation MI 
(STEMI) and non ST- elevation MI (non 
STEMI). STEMI usually develops 
secondary to a thrombotic and persistent 
occlusion of a coronary artery, not 
compensated by collateral flow14. Non 
STEMI is mostly caused by coronary 
thrombus associated either with subtotal or 
transient short-lasting occlusions or 
downstream embolization or with persist-
ent total occlusion, where preformed 
collaterals protect the jeopardized myo-
cardium15. Unstable angina pectoris (UAP) 
is a clinical syndrome characterised by 
sudden worsening of a previously stable 
angina, new-onset severe angina, or angina 
at rest16, 7.  
    In this heterogeneous spectrum, both 
high risk patients with ST depression or T-
wave inversion on ECG and /or minor 
elevation of biochemical markers not 
fulfilling the MI criteria and low risk 
patients without ECG changes indicating 
ischemia and no biochemical evidence of 
myocardial necrosis, can be identified. Due 
to a similar pathophysiology with often 
severe coronary artery lesions, a new 
formed thrombus obstructing the blood 
supply and high risk of new thrombotic 
events UAP and non STEMI are often put 
together into one entity as if these two 
conditions were more or less the same18,19 
In the year 2000, new guidelines on MI 
definition were introduced20. 
    Consequently, a substantial number of 
patients previously diagnosed with UAP, 
today fulfil the criteria for MI.   
 
Quality of life in coronary artery disease 
   Despite advances in treatment and 
preventive measures, ischemic heart 
disease is still imposing a considerable 
burden on the individual and on society. 
Morbidity after ACS includes both 
physical and mental disorders influencing 
the patient’s entire life situation and affects 
his/her quality of life (QoL)21,22 Lately, it 
has been increasingly common to include 
assessment of QoL in trials of CAD. 
Measurements of QoL are aimed to capture 
the patient’s own experience of health and 
illness in a broad perspective. The recog-
nition that the patients’ own perception of 
his/her health status may be as interesting 
as the standard clinical end-points is a new 
way of thinking in modern healthcare. A 
person’s perception of health and satis-
faction with life is very much affected by 
his or her expectations regarding health 
and ability to coupe with limitations and 
disability. For many patients with ischemic 
heart disease the ability to function in daily 
life, both physically and mentally is 
important. Feeling of well-being and to be 
able to participate in social life is also 
important and perceived cognitive function 
reflecting how to concentrate, activity 
drive, memory and problem-solving, has a 
major impact on QoL23. 
 
Gender perspectives in coronary artery 
disease. 
    The relatively low frequency of ACS in 
women as compared to men was first 
described by Heberden in the early 19th 
century. He described women to have a 
“protective factor” against coronary artery 
disease. In those days, women reached the 
age of 50 years, thus never entering 
menopause. Clearly, the relatively higher 
occurrence of ACS in men has during 
decades tended to undermine the 
importance of ACS as reason for morbidity 
and mortality in women. Today, ACS is 
the leading cause of death in both gender 
of the western world and during the last 
two decades there has been an ongoing 
debate about women and ACS and whether 
women and men suffering from this 
syndrome differ in baseline characteristics, 
clinical presentation, treatment and 
outcome24-27. Early mortality among 
patients hospitalized with an acute MI has 
been consistently reported to be higher 
among women than men28,29. An important 
question has been whether women tend to 
be treated less vigorously than men 
although current knowledge from a couple 
of studies strongly indicates that women in 
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most aspects benefit as much as men from 
recommended therapies30,31. In contrast to 
these studies, FRISC II and RITA 3 trials 
reported worsening outcomes among 
women with ACS who were treated 
invasively. This finding has raised doubt as 
to whether treatment in women and men 
should be similar32,33. 
    Among studies investigating the assoc-
iation between sex, age and early 
mortality, results differ from no assoc-
iation24,34, to worse prognosis in older 
women only35 or surprisingly worse 
prognosis only in younger women27,36. The 
higher short-term mortality among older 
women is explained by older age alone or 
in combination with a higher frequency of 
co-morbidities and a more complicated 
clinical course37. However, findings from 
the American National Registry of MI 
support a worse in-hospital mortality 
among younger but not older women with 
a linear increase in risk with decreasing 
age27. From our Swedish MI registry, 
Rosengren et al. reported in 2001 a higher 
in-hospital mortality among women below 
70 years of age36 The reasons for the sex-
age differences in early mortality remain 
unclear, although Vaccarino et al. 
explained in 1999 that younger, but not 
older women hospitalized with MI, 
suffered from more diabetes and 
congestive heart failure, as reason for 
worse short-term outcome among younger 
women27. Another possible explanation is 
gender differences in the management after 
MI38.  
    Reperfusion and other medically proven 
therapies used at the acute phase are less 
often used in both older and younger 
women compared with men. Moreover the 
higher rates of in-hospital deaths among 
younger women might be balanced with a 
higher rate of pre-hospital deaths in men39.  
    In contrast to studies on short-term 
mortality, several studies examining long-
term outcome among survivors after the 
acute phase, did not differ in mortality 
between women and men40,41 and some 
even found a more favourable outcome in 
women. The more favourable long-term 
outcome in women as compared with men, 
could be explained to some extent by the 
different life-expectancy of women and 
men42. Women may appear to have a 
similar or even better long-term outcome 
due to underlying survival advantage43. 
    Other studies investigating age-sex 
differences in long-term mortality beyond 
the hospital stay support higher long-term 
mortality rates among women, particularly 
younger women, compared with men at 
same ages. In a study from 2001, 
Vaccarino et al observed that women 
younger than 60 years of age had a higher 
mortality rate than men and the mortality 
risk for women compared with men 
decreased by increasing age, to the point 
where women in the oldest age groups 
showed a lower 2 year mortality rate than 
men of similar age36,44. 
 
Age perspectives in coronary artery 
disease 
    Clinical characteristics, treatment and 
outcome in patients with ACS differ not 
only due to gender but also between 
various age groups. Older individuals 
make the fastest–growing segment of the 
population in the western countries. CAD 
is highly prevalent and accounts for the 
majority of deaths in elderly people45. Thus 
they constitute an increasing percentage of 
patients admitted to hospitals for ACS and 
are a high risk population for which 
physicians and healthcare systems most 
probably should provide the same 
evidence-based ACS therapy as in younger 
generations. Paradoxically, studies show 
trends toward underutilization of such 
therapy in the elderly46. The lack of 
evidence to guide treatment compounded 
by the high prevalence of co-morbidities 
among elderly may partly explain the 
under use of medical and interventional 
therapies in this population47,48. The 
underutilization of evidence-based cardiac 
therapies and higher mortality in older 
patients, reported from several studies, is 
increasing in each successive age group47. 
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    Thus, the practice of grouping older 
patients, i.e. patients >65 years, together as 
a single age group may obscure important 
age-associated differences. There are 
considerable differences as to management 
and outcome in patients with ACS <65 
years and >75 years37, 49. 
    Some authors have suggested that 
elderly with MI do not benefit and may 
even be harmed by thrombolysis50. In 
contrast, Stenestrand et al reported in 2003 
from the Swedish RIKS-HIA, that 
fibrinolytic therapy in patients with 
STEMI, 75 years and older, was associated 
with a reduction in the composite of 
mortality and cerebral bleedings after 1 
year51. Moreover, the beneficial effects of 
other pharmacologic therapies such as 
beta-blockers and statins have been shown 
to extend to the elderly patients52,53. The 
fact that elderly patients may not receive 
optimal treatment for ACS, despite the 
availability of proven, scientific evidence, 
emphasize the need for ongoing research to 
optimize therapeutic regimens and 
adherence for the rapidly growing elderly 
population at high risk. 
 
Management and treatment 
    The treatment of patients suffering from 
ACS has changed dramatically during the 
last two decades. Prompt and effective 
reperfusion therapy, using thrombolysis or 
preferably primary percutaneous coronary 
intervention (PCI), is the cornerstone in the 
management of STEMI54,55. Non STEMI 
and UAP are more heterogeneous groups, 
which in clinical practice has led to a 
greater variation in diagnosis and treat-
ment. For non STEMI ACS, expert 
guidelines today recommend early risk 
stratification, effective antithrombotic 
therapy and a low threshold for 
angiography especially in high risk 
patients18,56. As to adjunctive therapy, 
current guidelines for STEMI and non 
STEMI ACS are more or less the same 
with beta-blockers, angiotensin converting 
enzymes (ACE) inhibitors, antiplatelet 
agents and statins included in the 
therapeutic strategy for most patients 
already in the acute phase. The long-term 
treatment is, irrespective of type of 
syndrome, based on an aggressive risk 
factor modification.  
    To stop smoking is crucial, hypertension 
and hyperglycaemia should be treated and 
cholesterol lowered. Beta-blockers 
improve prognosis and ought to be 
prescribed to all patients with an episode of 
ACS. Lipid lowering therapy should be 
initiated as soon as possible. Statins are 
known to reduce morbidity and mortality 
in women and men with CAD. Beside the 
improvements on the lipid profile, the 
statins seem to stimulate the endothelial 
function and reduce the inflammatory 
response of the plaque. In a study from 
2000, Ysuf et al. showed beneficial risk- 
reducing effects of ACE inhibitors on 
morbidity and mortality in patients with 
CAD57. Thus, ACE inhibitors should be 
prescribed to all patients with CAD and to 
all patients with left ventricular dys-
function irrespective of origin. 
    In spite of these advances in manage-
ment of ACS, the rate of cardiovascular 
mortality after discharge in still high.  
 
Prognosis 
    With many therapeutic options available 
the clinician is challenged to identity type 
of syndrome, make an early risk factor 
assessment and offer the safest and most 
effective treatment for survival of each 
individual patient. 
    Data regarding prognosis in populations 
covering the whole spectrum of ACS are 
scarce. Considerable variability exists in 
risk for adverse events across the whole 
spectrum of ACS. Difference in clinical 
characteristics at presentation identified as 
varying risk variables, are now important 
factors in deciding on the level of care and 
choice of interventional and medical 
therapies58,59. Current guidelines from the 
American College of Cardiology/ 
American Heart Association and the 
European Society of Cardiology56 
recommend certain pharmacological and 
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interventional strategies as standard 
therapy in high-risk patients. A number of 
multivariable prognostic models have been 
developed in populations of patients with 
STEMI60,61 and with non-STEMI 
ACS58,62,63. Most of these models are 
derived from databases in clinical trials 
leading to some of the most powerful 
predictors on mortality developed in the 
selected population of patients with 
STEMI treated with thrombolytics and 
consequently not relevant in all cardiac 
patients61,64. In 2003, the multinational, 
observational Global Registry of Acute 
Coronary Events (GRACE) developed, in 
order to determine factors predictive of 
death across the entire spectrum of ACS, a 
multivariable, prognostic model. A few 
variables were found to be consistent, 
powerful predictors of risk for hospital 
mortality in ACS. These were Killip class, 
age, blood pressure, cardiac arrest, positive 
findings for biochemical markers, 
creatinine level, ST-segment shift and 
heart rate65. 
    It is important to realize that variables 
predictive of a poorer short-term outcome 
following ACS are not necessarily those of 
most importance for the long-term 
outcome and vice versa.  
    Long-term prognosis of ACS survivors 
varies substantially according to 
conventional risk factor profile. Risk 
stratification for these patients is rather 
scarce. Factors identified from prior 
studies to be predictive of death in the long 
run include demographics (age and 
gender), predisposing conditions and 
behaviours (diabetes mellitus, hypertension 
and smoking) and prior cardiovascular 
events (stroke, previous MI)66. Other 
authors emphasize the prognostic value of 
baseline renal dysfunction in patients with 
ACS. Renal dysfunction is shown to 
independently predict higher mortality in 
patients with ACS67,68. The under-
utilization of reperfusion therapy in 
patients with renal dysfunction may 
contribute to the poor outcome  
    Diabetes mellitus is a major contributor 
to CAD and associated with substantially 
increased mortality and morbidity69. 
Recent evidence support early revascu-
larization in high-risk ACS patients. 
Diabetic patients subjected to coronary 
interventions are known to have a higher 
risk for complications and poorer 
prognosis than non-diabetic subjects. 
Although diabetes remained an 
independent and important risk factor for 
death, Norhammar et al showed in a study 
from 2004, that an invasive strategy 
improved 1 year outcome for both diabetic 
and non-diabetic patients with unstable 
angina pectoris70. 
    Smoking is a risk factor for chronic 
CAD and also known to strongly predict a 
poorer long-term outcome after ACS. A 
paradoxical survival advantage to current 
or prior cigarette smoking in patients 
admitted with ACS has been observed. The 
GRACE investigators clearly demonstrated 
in 2005 that the smokers’ paradox does not 
exist; there are no beneficial effects in 
smokers with ACS71,72. 
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AIMS OF THE PRESENT STUDY 
__________________________________________________________________________ 
 
In this prospective study of consecutive “real life” patients < 80 years of age with different 
types of acute coronary syndromes, treated in a coronary care unit, the following aims were 
selected for the present thesis: 
 
• To study gender differences in baseline characteristics, clinical presentation and 
treatment in relation to age and type of syndrome.  
 
• To study gender differences in terms of short- and long-term morbidity and mortality 
and to identify factors predictive of late death among women and men surviving the 
acute phase of an acute coronary syndrome. 
 
• To analyse whether there are similarities and differences in risk factors, previous 
history, clinical presentation, management, complications and short-term and long-
term outcome in patients with different types of the syndrome.  
 
• To evaluate whether elderly patients are managed differently from younger ones and 
to examine differences in morbidity and mortality in relation to age 
 
• To study quality of life at a 3-month follow-up in patients with acute coronary 
syndromes, with the main objective of exploring whether unstable angina pectoris and 
myocardial infarction patients differ in this respect. 
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MATERIALS AND METHODS 
__________________________________________________ 
 
Study population  
Patients admitted to the coronary care 
unit (CCU) of Sahlgrenska University 
Hospital, Göteborg, Sweden between Sept 
15, 1995 and Sept 15, 1999 with suspicion 
of ACS, were evaluated for participation in 
a study on prognosis and its prediction in 
ACS in real life (PRACSIS = Prognosis 
and Risk of Acute Coronary Syndromes in 
Sweden). Our hospital serves half of the 
450.000 inhabitants of the city of Göteborg 
and is also a tertiary centre for the Western 
Health Care Region of Sweden with 1.5 
million inhabitants. To enable long-term 
follow-up only patients under the age of 80 
and living within the hospital’s catchment 
area were eligible for the study. Patients 
transferred from other hospitals for tertiary 
care were not included, nor were patients 
with ACS treated outside the CCU. The 
study was approved by the ethics 
committee of Göteborg University. 
The suspicion of ACS had to be 
supported by ECG changes on admission 
(ST elevation ≥0.1mV (0,2 mV in V1-V4) 
or ST depression ≥0.1mV or T wave 
inversion in at least two adjacent leads), 
biochemical markers above the upper 
reference level (creatine-kinase (CK)-MB 
5µg/l and/or troponin T 0.05 µg/l), or 
previously recognized coronary artery 
disease, such as MI, prior PCI or coronary 
artery bypass grafting (CABG), stable or 
unstable angina pectoris with significant 
angiographic changes, or an exercise test 
suggestive of ischemia . The exclusion 
criteria were severe non- cardiac disease 
with expected survival less and 1 year, and 
unwillingness to participate. A patient 
could only be included once.  
 
Figure 1 
      Total number n = 1744 
  Patients < 75 years  n = 1357 
Patients alive after 3 months  n = 1263 
    Patients on 3 month 
 follow-up visit n = 1093 
Patients missing 3 month 
   follow-up visit  n=170 
Patients with information on  
       quality of life n = 814 
Patients without information  
    on quality of life n = 279 
Patients not included in  
     the study  n = 449 
Only 8 eligible patients fulfilled the 
exclusion criteria. A further 29 with UAP 
and 52 with acute MI were missed for 
logistic reasons. In all 1,854 patients were 
enrolled in the study. Among these 110 
were finally discharged with a diagnosis 
other than UAP or MI despite an initial 
strong suspicion of an ACS. 
This thesis deals with the 1,744 
patients (546 women and 1198 men) with a 
definite diagnosis of UAP or acute MI. 
They were retrospectively divided into four 
groups in assumed decreasing order of 
severity based on ECG and biochemical 
markers of myocardial ischemia and 
necrosis (1) STEMI with ST segment 
elevation or left bundle branch block and 
CK-MB >10 µg/l and/or troponin T ≥0.15 
µg/l, n= 622; (2) non-STEMI with CK-MB 
>10 µg/l and/or troponin T ≥015ug/l, 
n=594; (3) high-risk UAP with ST 
depression ≥0,1mV or T- wave inversion 
and/or CK-MB 5-10 µg/l and/or troponin T 
0.05-0.14 µg/, n=226; and (4) low-risk 
UAP with typical symptoms but without 
ECG changes indicating acute ischemia 
and CK-MB ≤5µg/l and troponin T <0.05 
µg/l, n=302. The patients were also divided 
into three groups according to age: <65 
years, 65-74 years, and 75-79 years. 
In Paper 3, only patients below the age 
of 75, who accepted an invitation to 
follow-up visit at the out-patient clinic 3 
months after discharge were eligible for 
participation. The flow of patients is illust-
rated in Fig. 1. In this paper the two main 
groups, UAP or MI, were created on the 
basis of hospital discharge diagnosis.  
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Data collection 
    Data were collected from the hospital 
medical records, including information on 
previous clinical history, risk factors and 
medication. While hospitalized, the study 
patients also passed a detailed interview 
conducted by an experienced study nurse. 
The time for onset of symptoms, the delay 
times, clinical presentation and ECG 
appearance on arrival, as well as ECG 
changes during the hospital stay were 
registered. Twelve lead ECG recordings at 
50 mm/s were used. Diabetes was defined 
as a previously known diabetes mellitus. 
Similarly, hypertension and hyper-
cholesterolemia were defined as previously 
known disorders and revealed by interview 
or registered in previous hospital records.  
The research nurse registered height 
and weight. Body mass index (BMI) was 
calculated as (body weight, kg)/ (height, 
m2). During the hospital stay, detailed 
surveys of the most important comp-
lications, medical treatment and 
investigations were made. At discharge, 
medical treatment, planned investigations 
and revascularization procedures, as well 
as the time spent in hospital, were 
documented. In- hospital mortality and 
mortality within 30 days were recorded. 
Information on deaths within five years as 
well as survival confirmation at five years 
was obtained from the Swedish National 
Population Register. Information on cause 
of death and readmission to hospital were 
obtained from the Swedish Cause of Death 
Register and the Swedish Hospital 
Discharge Register and was available for 
45 months follow-up for all patients. Short-
term mortality was defined as deaths 
within 30 days and late long-term mortality 
as death between 30 days and 5 years.  
 
Quality of Life Instrument (paper 3) 
    The Cardiac Health Profile (CHP) a 
disease-specific questionnaire for assessing 
health-related QoL, was used. It has been 
developed, tested and found to be reliable, 
valid and sensitive in a Swedish population 
with cardiovascular disease. The question-
naire consists of three parts. Part 1 assesses 
the self-reported degree of angina pectoris 
according to the modified CCS 
classification. The second part assesses 
health- related QoL in a broad perspective 
and consists of 16 questions including 
physical function/general health, social 
function, emotional function and cognitive 
function. Part 3 deals with patients who 
have had interventional treatment in one 
way or another and was not applicable to 
our study. The CHP results can be 
analyzed per item, as the four independent 
domains or as a total score. In this study 
we focused on the global mean score 
(GMS), but we have also looked separately 
at the scores in the four domains. The 16 
items and four domains in the English 
version of the questionnaire are shown in 
Appendix 1.  
 
General comments 
    The present study was conducted in a 
coronary care unit at a University Hospital 
with catheterization laboratories and 
cardiac surgery facilities in the second 
largest city of Sweden. People dying 
outside hospital were for obvious reasons 
not included, which means that more men 
than women were lost from participation at 
this very early stage39.  
    Our hospital’s catchment area is half of 
the inhabitants in Gothenburg, thus a 
strictly urban population from areas with 
slightly better socioeconomic circum-
stances than the other half of the city. We 
can therefore not exclude a survival 
advantage in our patients compared to the 
total Gothenburg ACS population73. No 
octogenarians participated in the study. 
The findings we did in our highest age 
group, with an increasing number of 
women and patients with non ST-elevation 
MI, would therefore have been further 
strengthened if no upper age limit had been 
set74,75. We know from previous studies at 
our hospital, that 20-25% of patients with 
ACS below 80 are treated in internal 
medicine wards76. An analysis of these 
patients from 1998 showed a somewhat 
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higher proportion of females than in our 
study (39% vs. 31%) and a higher 
proportion of non STEMI. (unpublished 
data). They were with very few exceptions 
not subjected to invasive procedures. 
In order to provide data on the entire 
spectrum of ACS, the GRACE project was 
designed some years ago. With a similar 
goal two Euro Heart Surveys on ACS have 
been conducted74,75. An interesting finding 
is that our ACS population is slightly older 
in spite of our upper age limit of 80 years, 
the percentage of women is similar or 
higher, and our mortality is higher than 
what has been presented from these 
projects. This indicates that we in spite of 
the limitations above in comparison with 
other similar reports have a satisfactory 
representation of the spectrum of ACS.  
In comparison with studies on ACS 
from national registries we have the 
advantage of higher quality on our data. 
One experienced study nurse made all the 
interviews and collected data from the 
hospital medical records. If information 
obtained from these interviews differed 
from those in the medical records a 
thorough work-up was done to resolve the 
discrepancies 
Our study was conducted before the 
new guidelines on infarct definition were 
introduced. During the entire study period 
serial measurements of CK-MB was the 
routine method for MI diagnosis at the 
hospital. Although additional measurement 
of troponin-T was recommended for the 
patients participating in the study, data 
turned out to be missing in a fairly high 
proportion of patients. This means that no 
retrospective subdivision of patients 
according to modern diagnostic criteria 
have been possible. Obviously some 
patients in our high risk UAP group would 
today have been diagnosed with non 
STEMI.  
There have been great advances in the 
management and care of ACS patients 
during recent years. One could argue that 
our data are fairly old and therefore not 
relevant for ACS patients of today. 
However, the frequencies of coronary 
angiographies as well as revascularization 
procedures were quite high in our study 
and well comparable with more recent 
figures from studies on ACS77. 
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STATISTICS 
__________________________________________________ 
 
 
In Paper 1 and 2, age-adjusted p-values were calculated using logistic regression for 
dichotomous variables and Spearman’s partial rank correlation for ordered/continuous 
variables. To test for associations with severity of ACS and with ordered age groups, Mantel-
Haentszel’s chi-square test was used. ACS was regarded as an ordered variable with 
decreasing severity from ST-elevation MI to low-risk type unstable angina. Interactions were 
tested using logistic regression models. 
 
For the univariate analysis in Paper 3, the association with CHP score was tested using the 
Mann-Whitney U test for dichotomous variables and Spearman’s rank statistics for 
continuous variables. Group comparisons of characteristics, clinical course, treatment and 
medication were made using Fischer’s exact test for proportions and the Mann-Whitney U-
test for age and length of hospital stay.  
 
Multivariate analyses were performed using a logistic regression model, in which the CHP-
scores of all 814 patients were divided into quartiles (i.e. by the 25th, 50th and 75th 
percentiles, which corresponded to a CHP score of 20, 32 and 46 respectively) as an ordinal 
four-graded response variable. 
 
In Paper 4, Kaplain-Meier estimates were used and tests were performed using the log rank 
rest. Cox proportional hazard model was used for adjusted comparisons, hazard ratio 
cacluclations (adjusted as well as unadjusted) and for identification of predictors of late long-
term mortality. 
 
All p-values are two-tailed and considered significant if below 0.01 in paper 1 and 2 and 
below 0.05 in paper 3 and 4.  
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RESULTS 
__________________________________________________ 
 
Observations in Relation to Gender 
Baseline 
   Among the 1744 patients with ACS, 31% 
were women. Whilst the proportions of 
STEMI did not differ between genders, 
non STEMI was more common in men and 
UAP in women (Fig. 2).  
p=0.006
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Figure 2. Type of syndrome in relation to gender
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Figure 5. In-hospital treatment in relation to gender
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The frequency of diabetes was similar in 
women and men, as was the frequency of 
previous PCI. More than 50% of both 
genders were overweight. Regarding 
medication, at entry men were more often 
on aspirin whereas a higher proportion of 
women was treated with diuretics. Women 
delayed seeking medical care longer than 
men and had more often a longer stay in 
the emergency department. At entry 
women more often tended to present with 
normal ECG while right bundle branch 
block was more common in men as was a 
pathological ECG without signs of an 
acute ischemia (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
In Hospital - 30 days 
    Reperfusion therapy was given to 65% 
of the 194 women and 72% of the 428 men 
(p=0.50, age adjusted) with STEMI (Fig. 
4).  
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Figure 4. Reperfusion therapy among STEMI patients in relation to gender
 
 
 
 
 
 
 
 
 
 
 
PCI was used in 40% of the women and 
48% of the men (p=0.83, age adjusted). 
There were no significant gender 
differences with respect to in-hospital 
complications and all medical therapy was 
used in a similar frequency in women and 
men. Women were less likely to be 
scheduled for CABG after discharge while 
the use of PCI showed no gender 
differences. A tendency towards a some-
what more frequent use of diuretics at 
discharge in women was seen while beta-
blockers, ACE inhibitors, lipid lowering 
agents and aspirin were, in similar 
frequency prescribed to women and men 
(Figs 5 and 6).  
Figure 3. Baseline characteristics, delay and ECG at presentation in relation to gender
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Figure 6. Complications and discharge medication in relation to gender
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The short-term mortality did not differ 
between women and men; 6.4 versus 5.8 
(p=0.62) in-hospital and 8.2 versus 6.8 
(p=0.85) at 30 days, respectively. Six 
variables independently predictive of 
short-term mortality were identified. These 
were age, blood pressure <100mmHg, 
Killip class >I, cardiac arrest prior to 
admission, elevated creatinine levels at 
entry and atrial fibrillation. No significant 
gender differences were observed. 
 
Long-term follow-up 
The late (>30 days) five year mortality 
was 21.0% for women and 18.2% for men. 
After adjusting for age differences, the HR 
and corresponding 95% CI for a higher late 
five year mortality in women in relation to 
men, was 0.89 (0.70,1.13), p=0.34.  
Cardiovascular morbidity and mortality 
during 45 months are shown in Fig. 7. 
Before, but not after, adjustment for age 
there was a significant gender difference in 
readmission for congestive heart failure 
(CHF), p=0.005 and p=0.23, respectively. 
Neither unadjusted nor adjusted for age did 
women nor men differ significantly in 
terms of readmission for MI, revascul-
arization or cardiovascular mortality. 
 
 
 
 
 
 
 
 
 
 
 
Thirteen variables related to baseline 
characteristics and hospital course were 
identified as factors with a significant 
influence on late mortality in the whole 
group of patients. Of these, age, ST-
depression on admission, diabetes, current 
smoking, heart rate >100 on admission and 
a haemoglobin level below the normal 
limit were significant predictors of death in 
both gender. Previous CABG was 
significantly associated with death in men, 
as were atrial fibrillation, PCI and CABG 
during hospitalization, with a clear trend 
for previous CABG also in women. The 
situation was the other way around for 
cardiogenic shock/Killip class >I, i.e. 
significance in women and a trend in the 
same direction in men. Except for two 
variables there was no interaction between 
gender and factor, regarding mortality. 
These two were previous treatment with 
diuretics, which had a larger impact on 
prognosis in men, and a creatinine value on 
admission above normal upper limit, which 
showed a more marked importance in 
women.(Fig.8)(*=women, Ө=men). 
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Figure 7. Cardiovascular death and readmission to hospital during
45-month follow-up in relation to gender
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Observations in Relation to Type of 
ACS  
Baseline 
    A less severe type of ACS, UAP instead 
of MI, was associated with a higher 
prevalence of previous MI, angina, CABG 
and PCI, a progressing angina prior to 
admission, a history of hypercholestero-
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lemia, past smoking, ongoing treatment 
with beta-blockers, aspirin, lipid lowering 
agents, long-acting nitrates, calcium 
blockers or diuretics, admittance via 
emergency ward instead of direct to CCU, 
and a normal ECG on admission. There 
was no significant interaction between sex, 
severity of the syndrome and the studied 
variables (Fig. 9).  
 
 
 
 
 
 
 
 
 
 
 
 
In hospital - 30 days - 5 years 
    In hospital complications were 
associated with the more severe type of 
ACS, MI instead of UAP. In contrast, all 
coronary interventions, other than primary 
PCI, were performed more frequently the 
less critically ill the patients were (Fig. 10).  
 
 
 
 
 
 
 
 
 
 
 
 
     
 
Treatment with ACE inhibitors at 
discharge was the only prescribed drug 
with a significant relation to severity of 
disease (Fig. 11). The 30 day mortality was 
nearly twice as high in STEMI patients, 
compared with patients with non STEMI 
(12,4% versus 7,4%, p=0.004). The 30-day 
mortality was considerably lower in 
patients with UAP and did not differ much 
between the two groups (Figs. 11, 12).  
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Figure 11.  Discharge medication in relation to type of acute coronary syndrome
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Figure 12. Short-term mortality in relation to type of acute coronary syndrome
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Figure 10. In-hospital investigations in relation to type of acute
coronary syndrome
     There was no interaction between 
gender and type of syndrome regarding 
mortality. Non STEMI patients had higher 
late 5 year mortality than the other 
categories, 24%. 
    Survival in STEMI and UAP high risk 
patients were surprisingly similar (18% 
and 16%, respectively) with the lowest 5 
year mortality in UAP low risk (13%). HR 
with 95% CI for late 5 year mortality in the 
three other types of ACS in comparison 
with UAP low risk after adjustment for age 
was 1.66 (1.16-2.38) for non STEMI, 1.31 
(0.90-1.90) for STEMI and 1.20 (0.77-
1.89) for UAP high risk. After adjustment 
for all 13 clinical variables with impact on 
prognosis as previously described the HR 
for non STEMI versus UAP low risk was 
1.21 (0.80-1.81). When a comparison 
between non STEMI and STEMI was 
carried out with adjustment for age in 
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combination with each of the 12 prognostic 
factors (including all patients without 
missing data), one at a time, the largest 
influence on HR was seen from Killip class 
on admission, adjustment for which led to 
a larger difference in mortality between 
non STEMI and STEMI.  
    The two variables responsible for the 
largest decrease in HR, i.e. diminished 
mortality difference between groups, were 
ST-depression on ECG on admission and 
revascularization with PCI (HR and 95% 
CI unadjusted 1.36 [1.04-1.78], p=0.02, 
adjusted for age 1.26 [0.97-1.54], p=0.08 
and adjusted for all thirteen variables 1.02 
[0.75-1.37], p=0.92) Fig. 13. 
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Figure 14. Cardiovascular death and readmission to hospital during 45-month 
follow-up in relation to type syndrome
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Cardiovascular morbidity and mortality 
during 45 months are shown in Fig. 14.     
There was an overall significant 
relationship between type of syndrome and 
readmission for MI (p<0.0001), non 
elective revascularization (p=0.03) and 
cardiovascular mortality (p=0.002). A 
comparison between non STEMI and 
STEMI yielded HR and 95% CI of 1.61 
(1.11-2.33) for non elective revascul-
arization (p=0.01) during 45 months after 
adjustment for age. There was no 
significant difference between non STEMI 
and STEMI with respect to readmission for 
MI, total revascularization and hospital 
readmission due to CHF. There was a trend 
for difference in cardiovascular mortality 
(HR 1.50 [1.07-2.10], p=0.02 unadjusted 
and HR 1.38 [0.98-1.93], p=0.07) after 
adjustment for age.  
 
Observations in Relation to Age  
Baseline  
    An older age was associated with female 
sex, non STEMI, a history of cardiac 
diseases and ongoing treatments with 
cardiac drugs. Ambulance use, heart rate 
>100 bpm, Killip class II-IV and right 
bundle branch block were more common 
with increasing age. A lower age was 
associated with UAP low risk, previous 
PCI, hypercholesterolemia, current 
smoking and normal ECG on admission 
(Fig. 15).  
 
    Diuretic treatment and systolic blood 
pressure <100 mmHg were more common 
in younger women than younger men 
while this difference was absent or even - 
in the case of systolic blood pressure <100 
mmHg-reversed in older patients. 
    Hypercholesterolemia was more 
common among older women than older 
Elisabeth Perers 23 Acute Coronary Syndrome 
  
p<0.0001%
Figure 16. Reperfusion therapy in patient with
with STEMI in relation to age
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Figure 17. In-hospital treatment and investigations in relation to age
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Figure 19. Late (>30 days) five year mortality in women
and men in relation to age
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Figure 18. Medication at discharge in relation to age
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men, whilst this difference tended to be 
reversed with a lower age.  
 
In hospital - 30 days - 5 years 
    Patients with STEMI constituted 36% 
below 65 years of age, 35% between 65 
and 74 years and 36% at age 75–79. In the 
three age groups, 79%, 70% and 56% of 
STEMI patients underwent reperfusion 
therapy. Of all patients who underwent 
reperfusion therapy, the use of PCI 
decreased with increasing age; 59%, 39% 
and 31% in the three age groups, 
respectively, (p<0.0001) (Fig. 16). 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
    Complications and mortality was 
associated with increasing age as was 
length of hospital stay. The lower age 
group was associated with coronary 
angiography, PCI during hospitalization 
and, to a larger extent, lipid lowering, 
while treatment with diuretics and ACE 
inhibitors at discharge was more frequent 
in the higher age group. (Fig. 17,18) 
 
 
 
    The use of Warfarin and/or aspirin/ 
antiplatelets at discharge was lower among 
younger women than among younger men 
(p<0.0001), whilst this difference reversed 
with increasing age. The situation was 
opposite for diuretics, with a higher use 
among women than men in patients in the 
lower age group (p<0.0001), but lower 
among older group. The 30-day mortality 
was similar among women and men in 
each of the three age groups. Late 
mortality increased with age, with no 
significant differences between women and 
men to the point that men older than 74 
years had a higher mortality than women 
of similar age (p=0.04) (Fig 19) 
 
 
Quality of Life 
Non-participants  
    Data from the 814 patients included in 
the study was compared with data from the 
449 patients alive 3 months after index 
discharge and not attending follow-up 
and/or answering the questionnaire 
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correctly. The groups were similar 
regarding diagnosis, age and gender. 
Factors associated with poorer QoL were 
more prevalent in non participants, 
particularly in patients with UAP.  
 
Characteristics in UAP versus MI  
    Of 814 patients answering the question-
naire, 278 (34%) were discharged with the 
diagnosis UAP and 536 (66%) with MI. 
Current smoking was more common 
among MI patients as was in-hospital 
complications, except for recurrent angina. 
Hypertension, lipid disorder, previous 
cardiac diseases and interventions were all 
significantly more frequent in the UAP 
group. The frequency of revascularization 
prior to the 3 months follow-up visit (PCI 
and/or CABG) was similar in the UAP and 
MI group (54% vs 52%). 
Figure21. Boxplots describing the scores in the four domains at 
the 3 month follow-up for patients with UAP and MI
 
CHP in UAP vs MI. 
    The self-reported degree of angina in 
Part I of the CHP questionnaire differed 
between MI and UAP at the 3-month visit 
with significantly higher percentage of 
angina in the UAP group (p<0.0001). The 
total QoL scores (Part II of the 
questionnaire) at the 3-month follow-up 
were significantly (p=0.006) higher for the 
patients with UAP (median 34; 22, 50) 
than for those with MI (median 30; 19, 44), 
as illustrated in Fig. 20 (left panel).  
 
Figure 20. Boxplots describing the global mean score in Cardiac 
Health Profile at the 3-month follow-up for UAP and MI patients 
(left) and for patients in four groups with assumed decreasing order 
of severity (right)
 
    Analyses identifying the four in-
dependent domains showed that perceived 
cognitive function as well as physical  
function/ general health predicted a poorer 
QoL in UAP patients as compared to MI at 
the 3-month follow-up (p=0.03 and p> 
0.0001, respectively)(Fig. 21). 
   
   After a further subdivision of the ACS 
patients into four groups with assumed 
decreasing order of severity, patients with 
UAP of the low-risk type reported 
significantly more angina than the others 
(Part 1 of the questionnaire). The low-risk 
group had a median total QoL score of 38 
(24,52) vs 30 (16,44) for patients with 
high-risk UAP (p<0.002, Fig. 20, right 
panel). A median QoL score of 30 was 
seen in both types of MI patients.  
 
QoL in Relation to Characteristics of 
ACS Patients 
    Characteristics significantly associated 
with poor QoL included female sex, lower 
age, current smoking, hypertension, 
diabetes mellitus, a history of angina 
pectoris, previous MI, previous CABG, 
hospitalization for proven or suspected 
cardiac disease during the preceding year, 
heart failure, pulmonary disease, inter-
mittent claudication, other chronic disease 
and treatment with sedatives and anti-
depressants. Patients who had been 
subjected to CABG prior to the 3-month 
visit had a better QoL than patients who 
did not undergo heart surgery. Recurrent 
angina, ongoing treatment with anti-
diabetics, long-acting nitrates and 
sedatives/antidepressants were associated 
with a poorer QoL.  
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Multivariable Analysis of CHP in UAP 
vs. MI 
 
    Below this, there are eleven lines 
representing the odds ratios for UAP vs. 
MI patients, separately adjusted for each of 
the variables which significantly differed 
between the UAP and MI groups and 
significantly correlated to CHP scores. 
Finally, the bottom line represents the UAP 
vs. MI patients’ difference when simul-
taneously adjusting for all the eleven 
variables, given odds ratio of 1.39, 95% 
CI:1.03–1.87, p=0.03 for a poorer QoL in 
UAP. 
    The uppermost line in Fig. 22 represents 
the unadjusted odds ratios and corres-
ponding 95% confidence intervals for a 
poorer QoL in UAP vs. MI patients.  
<
0.50 1.00 1.50 2.00 2.50
UAP vs MI 
adjusted for:
Figure 22. Influence of clinical variables on the difference in
quality of life between UAP and MI patients
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DISCUSSION 
___________________________________________________________________________ 
 
The overall aim of the PRACSIS 
(Prognosis and Risk in Acute Coronary 
Syndromes in Sweden) study was to study 
prognosis and its predictors in a 
consecutive series of patients with ACS. 
This thesis focused on the clinical aspects 
of ACS and intends to carefully describe 
clinical features and short-and long-term 
morbidity and mortality of participants. 
 
Findings in Relation to Gender 
    Traditionally CAD has been considered 
a disease predominantly affecting men. For 
a long time women were not included in 
cardiovascular research programmes at all. 
Although the life-time risk of CAD is one 
in three among women, they are still not 
fully aware of their risk and perceive the 
chance of dying from breast cancer as far 
more likely than from CAD.  
    In the early 90´s greater attention was 
focused on women with CAD and since 
then an increasing number of studies have 
been published concerning women's 
cardiovascular health. There is an ongoing 
debate whether women and men differ in 
baseline characteristics, as to use of 
medically proven therapies and 
revascularization procedures and in 
outcome after ACS24-27.  
    On the whole, the differences we could 
demonstrate were smaller than expected. 
An important finding in our study was that 
early management strategies including 
reperfusion therapy, coronary 
angiographies and medical treatment in the 
acute phase seemed to be quite similar in 
women and men. However, out of the 
patients treated with reperfusion therapy, a 
tendency, although not significant, was 
observed where men to a larger extent 
achieved PCI as first preferred choice. The 
only significant gender difference 
regarding treatment was CABG planned on 
discharge which was more common in 
men. This finding is most probably 
reflecting less severe CAD in women as 
suggested in a number of previous studies 
and also observed by us when comparing 
the extension of coronary atherosclerosis in 
our women and men with non STEMI ACS 
who were subjected to coronary angio-
graphy (unpublished data)33,78. The women 
in the present study delayed seeking 
medical care longer than men and they had 
longer stays at the emergency department 
before transmission to the CCU. This is 
consistent with earlier studies79. Women’s 
cardiac symptoms are taken less seriously 
not only by doctors and other health care 
workers, but also by the women 
themselves. The women’s denial and 
dissimilation of the disease might be one 
reason for these findings80. The fact that 
women in our study presented with STEMI 
as often as men is not in accordance with 
previous studies81. A possible explanation 
to our finding is that a female patient with 
STEMI at our hospital was as likely as a 
man to be admitted to the CCU, whereas a 
somewhat higher pro-portion of women 
than men with non STEMI were treated in 
medical wards. According to previous 
studies from our hospital patients with 
ACS not admitted to the CCU tend to be 
older and more often women76,82, Unlike 
previous reports women in our study did 
not suffer from more or more severe 
complications during hospitalization than 
men and no statistically significant gender–
based differences were found in terms of 
early mortality24,25. Studies comparing 
survival in women and men after ACS, 
support higher short-term mortality in 
women.  
    Differences in baseline clinical 
characteristics, less use of medically 
proven therapies and fewer revascul-
arisation procedures have been used as 
explanation38. Another important aspect to 
consider is that death of a disproportional 
number of men before hospital admission 
may represent an inherent gender bias for 
clinical studies enrolling only hospitalized 
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patients. Thus, the higher in- hospital 
mortality among women, may be balanced 
by the deaths of an equivalent number of 
men before reaching hospital36,39,83.  
    Although most risk factors contribute to 
CAD in both men and women, the impact 
of individual risk factors might also be 
different. Furthermore, variables predictive 
of a worse short-term outcome following 
ACS are not necessarily of the same 
importance for a poorer prognosis long-
term and vice versa. We found older age, 
elevated creatinine, blood pressure 
<100mmHg, heart failure and cardiac 
arrest prior to admission as predicative 
factors of higher early mortality. No 
significant differences between women and 
men were observed.  
    The fact that impaired renal function is 
predictive of a poor short-term outcome 
seems to be in line with recent studies 
emphasizing the prognostic value of 
baseline renal dysfunction in patients with 
the entire spectrum of ACS. Goldberg et al 
found that worsening renal function at 
admission for STEMI patients is a 
powerful and independent predictor of in-
hospital and one year mortality and suggest 
that small elevations of serum creatinine 
may serve as a simple marker to identify 
patients at a very high risk67. Not 
unexpectedly, signs of hemodynamic 
instability were associated with higher 
early mortality in our study. Such signs are 
important components of all prognostic 
models for STEMI61, but lacking in most 
of the risk scores that have been developed 
for non STEMI ACS,  where ST-de-
pression on ECG and elevated troponins 
seem to be of greater importance65,84,85. 
Models for the entire spectrum of ACS are 
scares. However, the GRACE registry 
score was created from a population like 
ours and also includes indices of 
hemodynamic instability, and in addition, 
in agreement with our findings, prehospital 
cardiac arrest65.   
    In the present study there were no 
significant gender differences in terms of 
five- year mortality for patients in the 
younger age groups, but the mortality risk 
for men compared with women increased 
with increasing age, to a point that men 
older than 74 years had a significant higher 
long-term mortality than women of a 
similar age. Most studies on gender 
differences in long- term outcome among 
survivors of the acute phase, have found 
either no differences in mortality between 
women and men or even more favourable 
outcome in women40,41. The more 
favourable long-term outcome in women 
as compared with men could be explained 
by women’ underlying survival advantage. 
The fact that women are affected with 
CAD later in life and are supposed to have 
a less severe disease than men, may contri-
bute to the lower incidence and mortality 
from MI in women throughout life43. 
    As already pointed out, it is of great 
importance to realize that the variables 
predictive of short-term outcome following 
ACS are to some extent different from 
those of most importance for a poorer 
prognosis long- term. In the present study 
well-known risk factors for CAD, such as 
age, diabetes and smoking also turned out 
to be risk indicators for poor long-term 
prognosis.  In contrast to the fact that 
smoking does not influence the early 
outcome it was of great importance in the 
long run for both women and men in our 
study. Similarly, diabetes mellitus was a 
strong predictor for an adverse long-term 
outcome in both genders. Diabetes mellitus 
emerges as an important risk factor 
influencing clinical presentation, course 
and prognosis of ACS, in many studies69,86. 
    About 20 percent of patients with MI 
have known diabetes. An even greater 
proportion of the MI patients have 
previously undiagnosed diabetes or 
impaired glucose tolerance when arriving 
in the CCU70. Diabetes is associated with 
markedly increased risk of MI and 
cardiovascular mortality in both women 
and men although women seem to be more 
vulnerable to the devastating effects of 
diabetes, which our data also indicate53,62.   
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    In our analysis the occurrence of atrial 
fibrillation (AF) influenced the long-term 
outcome negatively in both genders but 
only significantly in men. AF occurring 
after MI may occur alone or in association 
with other complications. The prognostic 
significance of new-onset AF in patients 
with ACS has been determined lately and 
AF is found to be an independent predictor 
of a worse outcome87,88. However, limited 
information is available about the different 
impact of AF in gender. Further efforts to 
identify these high-risk patients are needed 
so that appropriate therapies can be 
targeted to this high-risk cohort in order to 
improve their hospital and, potentially, 
long-term outcomes. 
    Treatment with diuretics was, much to 
our surprise, associated with a poorer long-
term outcome for men but not for women. 
Diuretic treatment at entry was more 
common among women. It is well-known 
that diuretics are quite often prescribed to 
women as antihypertensive drugs whereas 
other treatment strategies are chosen in 
men89. Men treated with diuretics on 
admission to hospital, had probably 
correctly been diagnosed with heart failure, 
which may explain their poor outcome. A 
man on diuretics might be in a poorer 
condition compared with a woman, where 
diuretics often have been prescribed due to 
breathlessness and leg oedema without 
association with CHF, or for treatment of 
hypertension.  
    Coronary revascularization (PCI/CABG) 
during index hospitalization was associated 
with improved long-term survival in men 
in our study, an observation consistent with 
the GRACE risk model and the PRAIS UK 
Registry90,91. In contrast, previous CABG 
was significantly associated with death in 
men and a clear trend in the same direction 
was seen in women. 
    ST-depression on admission emerged as 
a risk factor for death long-term in both 
gender in our analyses. Data from the 
GUSTO IIb study, including the entire 
spectrum of ACS, indicate a higher early 
mortality in those presenting with ST-
elevation compared with ST-depression. 
By 20 days the mortality curves had 
crossed and at 6 months mortality was 
higher in patients with ST-depression 
compared with ST-elevation92.  
 
Findings in Relation to Type of 
Syndrome 
The majority of recent studies have 
focused either on MI patients or patients 
with non STEMI ACS and only a few have 
included patients with a broader range of 
ACS's33,93. Thus, studies on a population 
like ours including patients covering the 
entire spectrum of ACS are scarce. In our 
study patients with STEMI delayed 
seeking care less often than other patients 
with ACS and this condition was most 
frequently associated with impaired 
hemodynamics, findings that are in 
accordance with previous reports94. 
Patients presenting with less severe type of 
ACS in our study, were to a larger extent 
burdened with a previous cardiovascular 
history and heavy ongoing medical 
treatment, reflecting prior contact with 
medical facilities. In this respect there was 
a distinct difference between patients with 
STEMI and those with UAP, with the non 
STEMI patients in between. In agreement 
with these findings, most trials on ACS 
without ST elevation report a higher 
frequency of risk factors and previous 
diseases than trials on STEMI95.  
The proportion of patients being 
reperfused was somewhat higher in our 
study compared with others. Thrombolytic 
therapy was given in 38% of patients with 
STEMI and primary PCI was performed in 
32%. In the large Euro Heart Survey of 
ACS, 35.1% received fibrinolytic therapy 
and 20.7% PCI and in GRACE study from 
2002 the corresponding figures were 47% 
and 18 %, respectively96,97.  
There have been great advances in the 
management and care of patients suffering 
from all types of ACS during recent years. 
One could argue that our data are fairly old 
and therefore not relevant for ACS patients 
of today. However, the frequencies of 
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coronary angiographies as well as 
revascularization procedures were quite 
high in patients with non STEMI ACS in 
our study and well comparable with more 
recent figures from studies on ACS77. This 
means that the treatment strategies we 
applied in our patients are in congruence 
with how many ACS patients in Sweden 
and Europe are handled today. 
    The more frequent use of intravenous 
medical therapy in our study was due to a 
higher rate of complications in STEMI 
patients, compared with non STEMI 
patients. Other authors report the same 
finding96. When our study was conducted, 
the early intervention strategy, 
recommended by current guidelines, was 
not fully implemented and consequently 
the highest frequency of coronary 
angiography, PCI and CABG, was seen in 
women and men with UAP. However, in 
most respects, the non STEMI patients had 
more similarities with the STEMI patients 
than with the UAP patients.  
    The hospital death rate for patients in 
thrombolytic trials such as GRACE study 
and the Euro Heart Survey (EHS) is 7% 
which is considerably lower than the death 
rate for patients with STEMI in our study 
(11.6%)77,96,97. The fact that we included 
patients who were dying on admission may 
contribute to the high hospital death rate in 
our STEMI group. The mortality at 30 
days was nearly twice as high in patients 
with STEMI compared with non STEMI 
patients. The hospital and 30 day mortality 
rates in the other types of ACS were lower 
than the rates found in GRACE study, 
probably due to our easy access to an on-
site facility for cardiac catheterization and 
thoracic surgery. 
    Relatively limited data are available on 
the long-term outcome in patients with the 
whole spectrum of ACS and classified 
according to modern principles. The 
patients that did worse in the long run were 
those with non STEMI. In contrast, the 
outcome for STEMI patients, who did 
worse in the acute phase, was comparable 
to that among patients with UAP. This 
result is in line with older reports on 
unfavourable outcome in patients with non 
Q-wave MI and there are also a couple of 
recent reports on patients categorised 
according to modern principles, like our 
study, with similar findings98,99. As already 
described patients with non STEMI were 
treated less aggressively than patients 
suffering from UAP at the time of 
inclusion in our study. The UAP group was 
more often subjected to coronary 
angiography and revascularisation 
procedures. In a comparison between non 
STEMI and STEMI with adjustment for 
age and prognostic factors, one at a time, 
adjustment for two of the factors, ST-
depression on ECG on admission and 
revascularization with PCI, resulted in a 
decreased difference in long-term mortality 
between non STEMI and STEMI. Thus, 
one reason for the high mortality in our 
non STEMI group might be the low rates 
of early intervention. The fact that patients 
with non STEMI have a poorer long-term 
outcome compared with other types of 
ACS, have also been previously explained 
by a greater burden of associated co-
morbidities and differential pathogenesis15. 
Patients with non STEMI in our study were 
to a larger extent burdened with previous 
MI, heart failure, AF and diabetes. 
Variable risk burden, stresses the 
importance of aggressive risk analyses and 
treatment of ACS during the acute phase, 
with emphasis on patients with non STEMI 
as a group at high risk.  
There are limited data on morbidity after 
hospitalization for ACS. Our figures 
indicate an overall relationship between 
type of syndrome and readmission due to 
MI, non elective revascularization and 
cardiovascular mortality. An age adjusted 
comparison within 45 months between non 
STEMI and STEMI, show significant 
differences for acutely performed 
revascularization. 
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Findings in Relation to Quality of Life 
    Quality of life (QoL) is an area of study 
that has attracted an ever increasing 
amount of interest over the past decades. A 
substantial number of studies have been 
performed in patients with MI69,100. Studies 
comparing QoL in patients with unstable 
angina and MI are few. In this study, 
covering the whole spectrum of ACS, we 
found a diagnosis of unstable angina 
associated with a poorer QoL than that of 
MI. Furthermore, our data indicate that it is 
the subgroup of patients with estimated 
low prognostic risk that experiences the 
poorest QoL. Our findings also indicate 
that factors in the patients’ characteristics 
and history influenced the QoL after the 
acute event more than clinical course and 
treatment during the hospital phase. 
    Among patients and laymen MI has 
always been considered as a very serious 
and life threatening condition. To be 
labelled MI might therefore from a 
psychological point of view have negative 
consequences for the patient and his QoL. 
Our study was not designed in order to 
capture patients’ reactions due to the 
diagnosis UAP or MI. We have no specific 
information about the perceived severity of 
disease among patients. Based on previous 
reports, a poorer QoL would have been 
expected in MI than UAP patients rather 
than the other way round. In order to avoid 
any potential influence from the diagnosis 
as such, the diagnosis at discharge was 
accepted without modification in our 
primary analysis. In some patients labelled 
as unstable angina the levels of CKMB or 
cardiac troponin T indicated that 
myocardial necrosis had occurred. Since 
our study was conducted before the latest 
guidelines for MI definition, a considerable 
number of those with unstable angina of 
high risk type should today have been 
diagnosed as MI. The fact that we did not 
find a poorer QoL in MI patients compared 
with UAP patients is reassuring. Due to the 
new definition of MI, an increasing 
number of ACS patients labelled with MI 
instead of UAP will be seen in the near 
future, which most probably won’t have a 
negative effect on QoL. 
    In accordance with the FRISC II trial, 
patient characteristics and previous history 
appear to be of greater importance for 
well-being at 3 months compared with the 
in-hospital course101. On the whole, the 
burden of previous diseases was larger in 
our UAP patients compared with MI 
patients.  
    Depression is an important risk factor 
for declining health in patients with ACS. 
In many recent studies, depression emerges 
as an important risk factor in terms of both 
cardiovascular morbidity and mortality and 
health-related QoL102. A substantial 
number of patients meet with depression 
following an acute coronary event. Our 
study was not designed to provide a 
satisfactory measure of depression, 
although questions related to depression 
are represented in the second domain of 
our CHP questionnaire. It is very likely 
that depression contributed to a poor QoL 
in some patients.  
    The symptom angina as such was more 
frequent among the UAP patients than 
those with MI in our study and seemed to 
impair the QoL. These findings are in line 
with previous studies69,100,103 . In several 
reports, improvements in QoL have been 
described after interventions in patients 
with both stable and unstable coronary 
disease and these improvements were 
found to be attributed to improvements in 
angina grade32,104. Besides the symptom 
angina as a predictor of poorer QoL, 
perceived cognitive function correlated to 
worse QoL in our study. Perceived 
cognitive function “reflecting a person’s 
perception of his or hers ability to select 
relevant information, and to understand, 
retain, express and apply knowledge in 
specific contexts”, has recently by 
Kiessling et al been evaluated as a 
predictor of worse QoL23. Perceived 
cognitive function was found to be the 
major determinant explaining a large 
proportion of the QoL, while only a small 
proportion was explained by perceived 
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physical functions/general health. Physical 
function but not cognitive function was 
related to CCS class. Perceived cognitive 
function was not related to the severity of 
the chest pain symptoms. Kiessling et al 
pointed out the importance of a QoL 
questionnaire including items reflecting 
cognitive function. The CHP instrument 
appears to be more sensitive, at least in 
some intervals, including questions about 
QoL in a broader perspective than most 
other instruments105.  
    Our findings that patients with low-risk 
ACS reported the poorest QoL are 
extremely important. These patients did 
not experience fewer anginas, but, in the 
absence of objective signs of acute 
ischemia, a conservative approach was 
chosen in many of these cases. Although a 
considerable number of patients were 
subjected to coronary angiography and 
PCI, they were less often scheduled for 
speedy invasive treatment than high risk 
UAP patients. One might ask whether the 
lack of attention, both with respect to 
interventions and invitations to 
rehabilitation programmes, which were 
mainly given to infarct patients, 
contributed to the low QoL associated with 
UAP of low risk type. They received less 
attention from health care professionals 
and even less support from relatives and 
friends than their high risk counterparts. 
Patients with low-risk angina spent a very 
short time in hospital and at discharge they 
got less detailed information. When home 
they feel uncertain as to the origin of pain 
and they have got inadequate information 
about disease mechanisms. In the future, 
we should consider that the current 
guidelines for treatment of ACS stress the 
importance of risk stratification and early 
identification of high risk patients. With a 
strict focus on outcome with respect to 
hard end–points we run the risk of 
neglecting the low risk patients. Their 
needs may be different but they certainly 
also should be given full attention and a 
careful follow up. 
 
Findings in Relations to Age 
    Elderly patients, those 65 years of age 
and older, represent a large proportion of 
western populations. They account for a 
considerable number of hospital 
admissions for ACS and deaths from MI. 
Despite the greater risk of MI among older 
patients and the increasing size of this 
population, the relationship between age, 
clinical presentation and outcome of MI in 
elderly patients is not completely 
understood.  
    The present study was not specially 
designed to study ACS in elderly people. 
Being part of a larger project with focus on 
long-term prognosis and risk in an ACS 
population treated in a CCU, the upper age 
limit for inclusion was set to 80 years.  
In contrast to the findings in the GRACE 
registry that older patients delay seeking 
care more than younger patients, we 
observed no significant differences in this 
respect between the three age groups46,94. 
Our elderly also seemed to use the mobile 
coronary care unit to the same extent as the 
younger ones.  
    In accordance with previous reports, we 
found a history of heart failure, previous 
MI and hypertension to be more common 
with increasing age, while hyperlipidemia, 
current smoking and prior PCI were 
considerably lower in the older age 
group26. Higher age was associated with 
less frequent use of coronary angiography 
and reperfusion therapy. Among all 
patients treated with reperfusion therapy, 
thrombolysis was the first preferred choice 
in elderly. Thus, also in our CCU, in line 
with suggestions from previous reports, 
elderly patients were less likely to undergo 
revascularization and to receive acute and 
long-term evidence-based medications 
when hospitalized with ACS26,49,106. The 
question is why? Are the lower rates of 
aggressive treatment due to elderly 
patients’ increased number of co-morbid 
conditions, physician or hospital effects, or 
true age-associated variation? The fact that 
evidence supporting the efficacy of acute 
reperfusion therapy in elderly with acute 
Elisabeth Perers 32 Acute Coronary Syndrome 
  
MI is not as strong as it is in younger 
groups may play some role. More data are 
available for thrombolysis than for PCI107. 
This is not true for other medications and 
actually, apart from the prescription of 
statins, there was no obvious under use of 
discharge medication related to age in our 
study. Our older patients received beta-
blockers and ACE inhibitors to a similar 
extent as the younger patients.  
    Instead of the under-utilisation of 
evidence-based therapies in the oldest 
group, these patients may due to their 
increased risk profile, benefit from 
application of medically proven therapy 
aiming at reducing the burden of disease to 
an even greater degree than in younger 
patients.    In our study as in a number of 
previous reports, older patients had a more 
complicated clinical course and a higher 
mortality than younger ones37,46,49. Short- 
term mortality as well as late mortality 
increased with age. Although age is an 
independent predictor of morbidity and 
mortality following acute MI, suboptimal 
management may further contribute to the 
high mortality in these patients. Our 
findings emphasize the ongoing need to 
better define and promote optimal 
therapeutic regimens for elderly patients 
with ACS. 
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SUMMARY 
___________________________________________________________________________ 
 
• Women are struck by ACS at a higher age than men and were, in the CCU setting, as 
likely to present with ST-elevation MI (STEMI). They were less likely to present early for 
hospital care and were attended to less rapidly in the emergency department. Women had 
lower rates of prior MI and prior coronary artery bypass surgery (CABG) than men but 
similar rates of percutaneous coronary interventions (PCI). At younger ages women were 
more likely to present with hypotension. 
 
• The management strategies including coronary angiographies and reperfusion therapy 
appeared to be similar in women and men, although a non-significant tendency of using 
PCI more often in men was observed. The only gender difference regarding treatment was 
CABG planned on discharge, which was more common in men. Women did not suffer 
from more severe complications or earlier death. 
 
• Among women and men surviving the acute phase of an ACS there was no difference in 
long-term mortality, while rehospitalization due to heart failure was higher in women 
before, but not after adjustment for age.  
 
• Out of a number of variables significantly associated with a poorer outcome, diuretic 
treatment prior to admission seemed to have a larger impact on prognosis in men and 
elevated creatinine to be of more importance in women. 
 
• Patients presenting with less severe type of ACS, UAP rather than MI, were to a larger 
extent, burdened with a previous cardiovascular history and heavy ongoing medical 
treatment. However, smoking was most common in STEMI 
 
• Severe complications including early mortality was associated with STEMI, while in the 
long run non STEMI patients had a poorer outcome than the other types of ACS. 
 
• After adjustment for co-variates the survival disadvantage for non STEMI disappeared. In 
addition to age, ST-depression on admission and revascularization with PCI seemed to 
have been of particular importance, indicating that a low rate of early interventions in the 
non STEMI group could be a factor of importance for a poor outcome. 
 
• Elderly patients were less frequently subjected to coronary angiographies and PCI. They 
had a more complicated clinical course and a poorer outcome. 
 
• Patients with unstable angina pectoris, especially of the low-risk type, experienced poorer 
quality of life following ACS than patients with other types of ACS 
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APPENDIX 
 
 Domains and items in the Cardiac Health Profile questionnaire (CHP)
Domains                                                  Items
• -------------------------------------------------------------------------------------------------------------
• Perceived cognitive function
• 1. How do you cope with tasks that require concentration and reflection?
• 2. Are you an active person, full of initiative or passive and listless?
• 3. Do you easily forget things in the immediate past or where, for example, you have placed things?
• 4. Do you easily understand and solve problems, make decisions, adapt to new situations?
• Emotional function
• 5. Do you feel depressed or have difficulty finding pleasure in things you used to find pleasant?
• 6. Do you easily become irritated, sad, worried, or anxious?
• 7. Do you often experience fear, uneasiness or anxiety?
• 8. Do you easily lose control over your feelings?
• Social function
• 9. Are you satisfied with your sleep (quality of sleep, ability to fall asleep etc.)?
• 10. Do you have a good relationship with those connected to you (family and friends)?
• 11. Are you satisfied with your daily life (at work, as a pensioner, as a housewife, as a student, etc.)?
• 12. Do you experience your leisure time as meaningful and enriching?
• Physical function/general health
• 13. How is your sexual life?
• 14. Are you satisfied with your physical capacity to accomplish things you wish to do?
• 15. How do you experience your general health status?
• 16. Are you troubled by various kinds of pain other than your known anginal chest pain?
• The answers are marked on a 100 mm VAS scale with verbal anchors. High scores indicate a 
• poorer Quality of Life. 
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